Search Bar & Filters
Found 197 Actively Recruiting clinical trials
Actively Recruiting
Researchers are evaluating the use of PET imaging with the radioligand 18FPI-2620 to detect tau protein buildup in people with Alzheimers disease and control subjects. This open-label, multi-center, pivotal Phase 3 study compares imaging results during life to brain tissue analysis after death to assess the accuracy and safety of this diagnostic method. Participants will receive an intravenous injection of 18FPI-2620 at a dose of 185 MBq 20%. This study is non-randomized and single-group, focusing on the imaging procedure itself without placebo or alternative treatments. The study will continue until autopsy and brain tissue analysis are completed, with an average follow-up period of about one year. During the study, participants will undergo PET scans using 18FPI-2620. Researchers will assess the scans ability to correctly identify tau pathology related to Alzheimers disease by comparing them to post-mortem brain tissue analysis. The study includes safety monitoring and evaluation of the agreement between different readers interpreting the scans. Overall participation lasts until the participants death and brain autopsy, expected on average around one year after the scan.
Actively Recruiting
Researchers are investigating the effects of an experimental drug called BNT323 also known as DB-1303 compared with standard chemotherapy in women with recurrent endometrial cancer that expresses the HER2 protein. This Phase III study includes two groups based on HER2 levels one group with lower HER2 expression 1 or 2 who have previously received immune checkpoint inhibitors, and another with higher HER2 expression 3. The study aims to evaluate how well these treatments control the cancer and their safety profiles. Participants in Cohort 1 will be randomly assigned to receive either BNT323 or a chemotherapy drug chosen by their doctor, such as doxorubicin or paclitaxel or docetaxel if paclitaxel is unsuitable. Cohort 2 participants will receive BNT323 alone. Treatments are given through intravenous infusions and continue until the cancer progresses, unacceptable side effects occur, or consent is withdrawn. The study includes screening, treatment lasting about six months, and long-term follow-up for up to 53 months to monitor survival and other outcomes. During the trial, participants will undergo various assessments including imaging scans to measure tumor size, evaluations of side effects, blood tests to study drug behavior and immune responses, and quality of life questionnaires. Safety follow-up occurs shortly after treatment ends, followed by extended monitoring for treatment effectiveness and survival. Participants are closely observed throughout to understand how well BNT323 works compared to chemotherapy and its impact on health and wellbeing.
Actively Recruiting
Researchers are evaluating treatments for germinal center B-cell-like diffuse large B-cell lymphoma GCB DLBCL, a fast-growing blood cancer affecting immature B-cells. The study aims to determine if more people respond to zilovertamab vedotin MK-2140 combined with R-CHP compared to polatuzumab vedotin combined with R-CHP. This is a phase 2 randomized study focused on participants who have not been treated before and have the GCB subtype of DLBCL. Participants will be randomly assigned to receive either zilovertamab vedotin plus cyclophosphamide, doxorubicin, rituximab or its biosimilar R-CHP, or polatuzumab vedotin plus R-CHP. These drugs are given by intravenous infusion on Day 1 of each 3-week cycle for up to 6 cycles, about 4 months. Additionally, participants take prednisone or prednisolone tablets daily on Days 1 to 5 of each cycle. Those with high-risk DLBCL may receive 2 extra cycles of rituximab or its biosimilar. Throughout the study, participants undergo assessments including PET scans to monitor cancer response, and various health evaluations. Researchers measure complete response rate at the end of treatment, progression-free survival, overall survival, event-free survival, and quality of life using standardized tools. Safety is monitored by tracking adverse events and treatment tolerability. The study lasts up to several years with follow-up for long-term outcomes.
Actively Recruiting
Researchers are investigating new treatments to prevent non-small cell lung cancer NSCLC from returning after surgery in people with high-risk, localized Stage I NSCLC. This Phase 3 randomized clinical trial compares adjuvant intismeran autogene V940 alone or combined with subcutaneous pembrolizumab and berahyaluronidase alfa against placebo in participants who have had their cancer completely removed. The goal is to improve disease-free survival in these patients. Participants are assigned to one of three groups one receives intismeran 1 mg by intramuscular injection plus pembrolizumab with berahyaluronidase alfa by subcutaneous injection another group receives intismeran alone by intramuscular injection and the third group receives a placebo injection. Treatments are given as part of the study, with dosing schedules and combinations designed to evaluate their effects on cancer recurrence. During the study, participants will be closely monitored through regular assessments including imaging scans and laboratory tests to track disease status and side effects. Researchers will measure outcomes such as disease-free survival, distant metastasis-free survival, overall survival, and quality of life using standardized questionnaires. Safety will also be monitored throughout the study, which may last up to several years for some participants.
Actively Recruiting
Researchers are evaluating the safety, tolerability, immune response, and pharmacokinetics of UGN-501, a chimeric oncolytic adenovirus, given directly into the bladder for adults with recurrent non-muscle invasive bladder cancer NMIBC. This Phase 1, open-label, dose-escalation study focuses on participants with high-grade and low-grade Ta andor T1 disease or carcinoma in situ CIS, aiming to find the recommended dose for further study. Participants will undergo a 12-week Induction Period with six weekly intravesical instillations of UGN-501. Those with certain disease types who respond or do not have recurrence will continue into a Maintenance Period, receiving three weekly instillations every three months from Month 3 to Month 12. Disease assessments occur every three months up to 15 months or until recurrence, progression, or death. The study may add other intervention arms or dose expansions in future amendments. During the study, participants will have regular evaluations including monitoring for dose-limiting toxicities, adverse events, drug levels in blood and urine, and immune response. Disease status will be assessed at specified intervals, with follow-up lasting up to 15 months. The main outcomes measured include safety, complete response rate at 3 months, and recurrence-free survival at 6 months, along with detailed pharmacokinetic and viral shedding analyses.
Actively Recruiting
Researchers are evaluating the safety and tolerability of NKX019, an investigational allogeneic CD19-directed CAR NK cell therapy, in adults with autoimmune diseases such as Lupus Nephritis and Primary Membranous Nephropathy. This Phase 12, open-label, multi-center study uses a dose escalation design to find recommended doses and assess preliminary effects, pharmacokinetics, and pharmacodynamics. Participants undergo a treatment cycle starting with lymphodepletion using fludarabine and cyclophosphamide or cyclophosphamide alone if cytopenic, followed by three doses of NKX019. The study uses a 33 dose escalation to determine safe dosing and includes dose expansion cohorts. The treatment aims to evaluate the impact of NKX019 on autoimmune disease activity and kidney function. During the study, participants are closely monitored for dose-limiting toxicities, adverse events, and lab abnormalities from the first dose until follow-up. Researchers assess kidney response, disease activity scores, and drug levels in blood for up to two years after infusion. Immunogenicity and effects on background therapies are also evaluated. The total participation time varies based on follow-up assessments and treatment response.
Actively Recruiting
Researchers are studying the safety and tolerability of NKX019, an investigational allogeneic CD19-directed CAR natural killer CAR NK cell therapy, in adults with autoimmune diseases. This Phase 12 open-label, multi-center, multi-cohort trial uses dose escalation and expansion to evaluate NKX019 in participants with conditions such as systemic sclerosis, idiopathic inflammatory myopathies, ANCA-associated vasculitis, and rheumatoid arthritis. The study aims to understand the treatments safety, preliminary effectiveness, pharmacokinetics, pharmacodynamics, and immunogenicity. Participants will undergo a cycle that starts with lymphodepletion using fludarabine and cyclophosphamide, or cyclophosphamide alone if they have low blood cell counts. This is followed by three doses of NKX019. The dose escalation follows a 33 design to find the recommended dose for further study. The study includes one treatment group receiving NKX019 combined with lymphodepleting drugs to assess safety and tolerability. During the study, participants will be closely monitored for dose-limiting toxicities within the first 28 days and treatment-emergent adverse events throughout treatment and 30 days after. Assessments include safety evaluations, pharmacokinetic measurements, and immunogenicity testing up to two years after infusion. The study also tracks effects on background therapies and disease-specific outcomes. Overall participation may last up to two years, with regular visits and evaluations to monitor health and treatment response.
Actively Recruiting
Researchers are evaluating the safety and early effects of a new neuronal cell therapy called NRTX-1001 for adults with drug-resistant bilateral mesial temporal lobe epilepsy MTLE. This open-label, single-arm study involves up to 10 subjects and aims to reduce seizure frequency by targeting both temporal lobes in patients whose seizures have not improved with medication. The investigational treatment uses inhibitory nerve cells called interneurons to potentially suppress seizure activity by releasing a natural brain chemical called GABA. Participants will receive a single administration of NRTX-1001 through a stereotactic CT or MRI-guided injection directly into both temporal lobes of the brain. The therapy is designed to persist long-term, so repeated doses are not planned. This phase 12 trial observes subjects closely for safety and seizure changes over two years after treatment. Following this period, participants will continue with less frequent follow-up phone calls every three months and yearly visits through year 15 to monitor long-term outcomes. During the study, participants will undergo evaluations approximately every three months for two years, including clinical assessments and seizure monitoring. Safety and tolerability will be specifically tracked, with the main outcome being the rate of serious adverse events at 12 months post-treatment. Seizure frequency changes will also be measured as a secondary outcome. After the initial two years, ongoing safety and health status will be followed through scheduled calls and visits for up to 15 years, emphasizing long-term monitoring and support.
Actively Recruiting
Healthy Volunteer
Researchers are evaluating DB-2304 in a Phase 12a study involving healthy adults and individuals with Systemic Lupus Erythematosus SLE or Cutaneous Lupus Erythematosus CLE. The study aims to assess the safety, tolerability, pharmacokinetics, and pharmacodynamics of DB-2304 for injection in these participants. This trial is randomized and double-blind, sponsored by DualityBio Inc., and includes adults aged 18 to 70 years. Participants receive different dose levels of DB-2304 or placebo, with some also receiving prednisone as part of their stable treatment regimen. The study includes two parts Part A with healthy adults aged 18 to 55, and Part B with adults aged 18 to 70 having SLE or CLE. Treatments are administered by injection, and participants are randomly assigned to one of several dose levels to evaluate different dosing effects. During the study, participants will undergo monitoring for treatment-emergent adverse events, serious adverse events, and various vital signs including ECG, heart rate, respiratory rate, body temperature, and weight. These measurements are tracked for up to 112 days after treatment in Part A and up to 280 days after the first treatment in Part B. The study involves regular assessments to evaluate safety and treatment response over these periods.
Actively Recruiting
Researchers are evaluating the use of pemigatinib for adults with advanced or metastatic pancreatic cancer that has spread locally or to distant parts of the body. This study focuses on patients whose cancer has specific abnormal changes in the FGFR gene, which can promote cancer growth. The goal is to see if pemigatinib can block these abnormal genes to stop tumor growth and improve quality of life. Participants take pemigatinib orally once daily for 14 days in each 21-day cycle, continuing as long as the cancer does not worsen or side effects are manageable. During the study, patients undergo blood tests, CT andor MRI scans, and optical coherence tomography OCT. Additional scans like whole body bone scans and eye exams may be performed if needed. After treatment, patients are followed up 30 days later and then every 4 months for one year. Throughout the study, researchers assess tumor response using imaging and blood tests, including monitoring cell-free DNA to track response and resistance. They measure overall response rate up to 24 months and evaluate progression-free survival, disease control, overall survival, and side effects up to 12 months. Safety and tolerability are closely monitored, and patients overall health and treatment effects are regularly checked to understand the impact of pemigatinib.
1-10 of 197
1